| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 72 | 2023 | 548 | 13.630 |
Why?
|
| Antitubercular Agents | 56 | 2023 | 318 | 6.810 |
Why?
|
| Tuberculin Test | 40 | 2023 | 132 | 5.420 |
Why?
|
| Latent Tuberculosis | 14 | 2023 | 82 | 5.350 |
Why?
|
| Mycobacterium tuberculosis | 36 | 2022 | 426 | 4.570 |
Why?
|
| Tuberculosis, Pulmonary | 36 | 2021 | 247 | 4.350 |
Why?
|
| Interferon-gamma Release Tests | 13 | 2023 | 87 | 3.740 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 8 | 2021 | 82 | 2.410 |
Why?
|
| Isoniazid | 8 | 2021 | 63 | 2.020 |
Why?
|
| Rifampin | 6 | 2021 | 191 | 1.890 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 12 | 2023 | 123 | 1.850 |
Why?
|
| Child | 121 | 2023 | 29154 | 1.660 |
Why?
|
| Child, Preschool | 75 | 2023 | 16273 | 1.450 |
Why?
|
| Directly Observed Therapy | 9 | 2018 | 21 | 1.410 |
Why?
|
| Mycobacterium Infections | 7 | 2010 | 49 | 1.390 |
Why?
|
| Tuberculosis, Pleural | 2 | 2022 | 11 | 1.250 |
Why?
|
| Infant | 55 | 2021 | 13310 | 1.100 |
Why?
|
| Lymphadenitis | 7 | 2014 | 39 | 1.080 |
Why?
|
| Antibiotics, Antitubercular | 2 | 2016 | 37 | 1.060 |
Why?
|
| Mycobacterium | 4 | 2010 | 56 | 1.050 |
Why?
|
| Contact Tracing | 5 | 2021 | 56 | 1.050 |
Why?
|
| Mass Screening | 11 | 2021 | 1509 | 1.040 |
Why?
|
| Adolescent | 69 | 2023 | 31252 | 0.980 |
Why?
|
| Fever | 2 | 2019 | 497 | 0.970 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 4 | 2019 | 31 | 0.930 |
Why?
|
| BCG Vaccine | 8 | 2021 | 399 | 0.880 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2022 | 33 | 0.880 |
Why?
|
| Mycobacterium abscessus | 2 | 2019 | 13 | 0.860 |
Why?
|
| Tuberculosis, Miliary | 2 | 2019 | 12 | 0.850 |
Why?
|
| Humans | 170 | 2023 | 261506 | 0.850 |
Why?
|
| Tuberculosis, Meningeal | 6 | 2023 | 30 | 0.840 |
Why?
|
| Tuberculoma | 2 | 2019 | 5 | 0.820 |
Why?
|
| Cost of Illness | 2 | 2014 | 498 | 0.780 |
Why?
|
| School Health Services | 4 | 2018 | 109 | 0.760 |
Why?
|
| Texas | 23 | 2020 | 6311 | 0.750 |
Why?
|
| Knee | 1 | 2019 | 33 | 0.700 |
Why?
|
| Central Nervous System Infections | 1 | 2019 | 19 | 0.690 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2019 | 12 | 0.690 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2019 | 71 | 0.670 |
Why?
|
| Tuberculin | 1 | 2018 | 18 | 0.640 |
Why?
|
| Medication Adherence | 5 | 2018 | 492 | 0.620 |
Why?
|
| Edema | 1 | 2019 | 267 | 0.610 |
Why?
|
| Drug Monitoring | 2 | 2019 | 333 | 0.600 |
Why?
|
| Emigrants and Immigrants | 4 | 2014 | 147 | 0.600 |
Why?
|
| Drug Administration Schedule | 9 | 2019 | 3472 | 0.590 |
Why?
|
| Hospitals, Pediatric | 9 | 2018 | 773 | 0.580 |
Why?
|
| Infection Control | 4 | 2013 | 270 | 0.580 |
Why?
|
| Interferon-gamma | 5 | 2020 | 1144 | 0.560 |
Why?
|
| Professional Impairment | 1 | 2015 | 5 | 0.540 |
Why?
|
| Incidence | 17 | 2020 | 5673 | 0.530 |
Why?
|
| Illness Behavior | 1 | 2015 | 29 | 0.530 |
Why?
|
| Rat-Bite Fever | 1 | 2014 | 4 | 0.520 |
Why?
|
| Streptobacillus | 1 | 2014 | 4 | 0.520 |
Why?
|
| Occupational Health | 1 | 2015 | 95 | 0.510 |
Why?
|
| Risk Factors | 28 | 2018 | 17523 | 0.510 |
Why?
|
| Infant, Newborn | 19 | 2019 | 8223 | 0.500 |
Why?
|
| Arthralgia | 1 | 2014 | 89 | 0.480 |
Why?
|
| Tuberculosis, Central Nervous System | 2 | 2007 | 11 | 0.480 |
Why?
|
| HIV Infections | 10 | 2017 | 2134 | 0.480 |
Why?
|
| Patient Care | 1 | 2014 | 149 | 0.460 |
Why?
|
| Hand Hygiene | 1 | 2013 | 14 | 0.460 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2011 | 234 | 0.460 |
Why?
|
| Male | 64 | 2021 | 123000 | 0.460 |
Why?
|
| Female | 67 | 2022 | 141928 | 0.450 |
Why?
|
| Cross Infection | 6 | 2014 | 544 | 0.440 |
Why?
|
| Drug Therapy | 2 | 2012 | 205 | 0.430 |
Why?
|
| Exanthema | 1 | 2014 | 211 | 0.430 |
Why?
|
| Tuberculosis Vaccines | 1 | 2011 | 12 | 0.420 |
Why?
|
| Pediatrics | 3 | 2018 | 1141 | 0.420 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2022 | 544 | 0.410 |
Why?
|
| Sensitivity and Specificity | 10 | 2021 | 4971 | 0.410 |
Why?
|
| Attitude of Health Personnel | 2 | 2015 | 918 | 0.410 |
Why?
|
| Population Surveillance | 2 | 2014 | 627 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 9 | 2022 | 2992 | 0.390 |
Why?
|
| Age Factors | 13 | 2021 | 5377 | 0.390 |
Why?
|
| Cystic Fibrosis | 4 | 2021 | 264 | 0.380 |
Why?
|
| Central Nervous System Bacterial Infections | 1 | 2010 | 6 | 0.370 |
Why?
|
| Mycobacterium avium Complex | 2 | 2019 | 29 | 0.370 |
Why?
|
| Global Health | 6 | 2020 | 657 | 0.350 |
Why?
|
| Adoption | 1 | 2008 | 14 | 0.330 |
Why?
|
| United States | 25 | 2016 | 15433 | 0.330 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 1581 | 0.330 |
Why?
|
| Retrospective Studies | 19 | 2021 | 37905 | 0.330 |
Why?
|
| Vaccination | 3 | 2011 | 1123 | 0.320 |
Why?
|
| Cross Reactions | 2 | 2021 | 266 | 0.310 |
Why?
|
| Nontuberculous Mycobacteria | 4 | 2021 | 44 | 0.300 |
Why?
|
| Disease Management | 2 | 2016 | 1052 | 0.300 |
Why?
|
| Paresis | 1 | 2007 | 54 | 0.290 |
Why?
|
| Physicians | 1 | 2015 | 882 | 0.290 |
Why?
|
| Drug Therapy, Combination | 8 | 2019 | 2315 | 0.280 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2008 | 193 | 0.280 |
Why?
|
| Brain | 1 | 2019 | 4113 | 0.280 |
Why?
|
| Endemic Diseases | 1 | 2006 | 67 | 0.270 |
Why?
|
| Quality Improvement | 1 | 2013 | 851 | 0.270 |
Why?
|
| Treatment Outcome | 13 | 2019 | 32848 | 0.270 |
Why?
|
| Tuberculosis, Spinal | 2 | 2013 | 12 | 0.270 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2013 | 202 | 0.260 |
Why?
|
| Emigration and Immigration | 2 | 2004 | 86 | 0.260 |
Why?
|
| Child Health Services | 2 | 2003 | 82 | 0.250 |
Why?
|
| Students | 2 | 2016 | 324 | 0.240 |
Why?
|
| Skin Tests | 3 | 2016 | 96 | 0.230 |
Why?
|
| Diagnosis, Differential | 9 | 2014 | 4744 | 0.230 |
Why?
|
| Respiration, Artificial | 2 | 2018 | 577 | 0.230 |
Why?
|
| AIDS-Related Opportunistic Infections | 6 | 2010 | 163 | 0.220 |
Why?
|
| Policy | 1 | 2023 | 49 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 1992 | 362 | 0.220 |
Why?
|
| Clostridium Infections | 2 | 2017 | 252 | 0.220 |
Why?
|
| Skin Diseases, Bacterial | 2 | 2014 | 44 | 0.210 |
Why?
|
| Pneumonia, Bacterial | 2 | 2015 | 130 | 0.210 |
Why?
|
| False Positive Reactions | 2 | 2021 | 355 | 0.200 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 4320 | 0.200 |
Why?
|
| Developing Countries | 4 | 2010 | 315 | 0.200 |
Why?
|
| Mycobacterium bovis | 1 | 2021 | 67 | 0.200 |
Why?
|
| Thorax | 2 | 2019 | 213 | 0.190 |
Why?
|
| Mycobacterium avium | 1 | 2000 | 22 | 0.190 |
Why?
|
| Uterine Cervical Diseases | 1 | 2000 | 25 | 0.190 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 1997 | 419 | 0.190 |
Why?
|
| Reference Standards | 3 | 2015 | 339 | 0.180 |
Why?
|
| Disease Outbreaks | 2 | 1992 | 415 | 0.170 |
Why?
|
| Time Factors | 3 | 2019 | 12926 | 0.170 |
Why?
|
| Pseudomonas Infections | 2 | 2013 | 156 | 0.170 |
Why?
|
| Radiography, Thoracic | 3 | 2011 | 462 | 0.170 |
Why?
|
| Personnel, Hospital | 2 | 2013 | 40 | 0.170 |
Why?
|
| Spotted Fever Group Rickettsiosis | 1 | 2018 | 4 | 0.170 |
Why?
|
| Rickettsia | 1 | 2018 | 9 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 5 | 2023 | 2403 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 1209 | 0.160 |
Why?
|
| Debridement | 1 | 2018 | 123 | 0.160 |
Why?
|
| Ventilators, Mechanical | 1 | 2018 | 50 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2016 | 203 | 0.150 |
Why?
|
| Health Personnel | 2 | 2015 | 625 | 0.150 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2016 | 994 | 0.150 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2016 | 173 | 0.150 |
Why?
|
| Health Education | 2 | 2016 | 309 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 698 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2019 | 441 | 0.150 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2018 | 441 | 0.150 |
Why?
|
| Angiostrongylus cantonensis | 1 | 2016 | 9 | 0.150 |
Why?
|
| Strongylida Infections | 1 | 2016 | 15 | 0.140 |
Why?
|
| Combined Modality Therapy | 4 | 2018 | 8865 | 0.140 |
Why?
|
| Surveys and Questionnaires | 5 | 2016 | 5687 | 0.140 |
Why?
|
| Fever of Unknown Origin | 1 | 2016 | 63 | 0.140 |
Why?
|
| Community-Acquired Infections | 2 | 2015 | 285 | 0.140 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 1995 | 10 | 0.130 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2015 | 29 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2014 | 363 | 0.130 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2015 | 70 | 0.130 |
Why?
|
| Bacterial Vaccines | 2 | 1995 | 103 | 0.130 |
Why?
|
| Aftercare | 1 | 2017 | 259 | 0.130 |
Why?
|
| Soft Tissue Infections | 2 | 2014 | 102 | 0.130 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2015 | 50 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2018 | 574 | 0.130 |
Why?
|
| Cat-Scratch Disease | 1 | 2015 | 35 | 0.130 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2015 | 62 | 0.130 |
Why?
|
| Botswana | 1 | 2014 | 87 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 7702 | 0.120 |
Why?
|
| Follow-Up Studies | 6 | 2014 | 14889 | 0.120 |
Why?
|
| Adolescent Behavior | 1 | 2016 | 230 | 0.120 |
Why?
|
| Clinical Trials as Topic | 3 | 2015 | 3719 | 0.120 |
Why?
|
| Prevalence | 3 | 2018 | 3260 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2016 | 621 | 0.120 |
Why?
|
| Communicable Diseases | 1 | 2016 | 193 | 0.120 |
Why?
|
| Risk Assessment | 4 | 2015 | 6869 | 0.120 |
Why?
|
| Sex Distribution | 3 | 2015 | 495 | 0.120 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2014 | 111 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2006 | 3869 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 2 | 2010 | 204 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 332 | 0.120 |
Why?
|
| Hospital Mortality | 2 | 2018 | 1274 | 0.120 |
Why?
|
| Age Distribution | 3 | 2015 | 698 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 945 | 0.110 |
Why?
|
| Drug Costs | 1 | 2014 | 144 | 0.110 |
Why?
|
| Drug Resistance, Microbial | 4 | 1999 | 218 | 0.110 |
Why?
|
| Inflammation | 2 | 2017 | 2522 | 0.110 |
Why?
|
| Poverty | 1 | 2016 | 471 | 0.110 |
Why?
|
| Clofazimine | 2 | 2022 | 8 | 0.110 |
Why?
|
| Cross-Cultural Comparison | 1 | 2012 | 87 | 0.110 |
Why?
|
| Osteomyelitis | 1 | 1995 | 236 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 761 | 0.110 |
Why?
|
| Family Health | 2 | 2011 | 325 | 0.110 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 418 | 0.110 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2011 | 8 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2015 | 330 | 0.110 |
Why?
|
| Nephrotic Syndrome | 1 | 2012 | 57 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 1994 | 244 | 0.100 |
Why?
|
| Young Adult | 7 | 2023 | 21445 | 0.100 |
Why?
|
| Allografts | 1 | 2014 | 650 | 0.100 |
Why?
|
| Markov Chains | 1 | 2012 | 175 | 0.100 |
Why?
|
| Referral and Consultation | 2 | 2013 | 899 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 4892 | 0.100 |
Why?
|
| Neoplasms | 3 | 2014 | 15193 | 0.100 |
Why?
|
| Diarrhea | 1 | 2015 | 686 | 0.100 |
Why?
|
| Immunization Schedule | 1 | 1991 | 117 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 1323 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 7551 | 0.100 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 87 | 0.100 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 233 | 0.100 |
Why?
|
| Mandatory Programs | 1 | 2010 | 7 | 0.100 |
Why?
|
| Drug Design | 1 | 2013 | 375 | 0.100 |
Why?
|
| Neck | 2 | 2008 | 383 | 0.090 |
Why?
|
| Steroids | 1 | 2012 | 356 | 0.090 |
Why?
|
| World Health Organization | 1 | 2011 | 316 | 0.090 |
Why?
|
| HIV | 1 | 2011 | 229 | 0.090 |
Why?
|
| Adult | 19 | 2018 | 77950 | 0.090 |
Why?
|
| Consensus | 3 | 2023 | 978 | 0.090 |
Why?
|
| Hospitals | 1 | 2013 | 485 | 0.090 |
Why?
|
| Coinfection | 1 | 2011 | 189 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 5 | 2010 | 3203 | 0.090 |
Why?
|
| Meningitis, Bacterial | 1 | 2010 | 89 | 0.090 |
Why?
|
| Carrier State | 1 | 2010 | 90 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2013 | 1085 | 0.090 |
Why?
|
| Public Health | 3 | 2016 | 299 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2014 | 2316 | 0.090 |
Why?
|
| Viral Vaccines | 1 | 1991 | 304 | 0.080 |
Why?
|
| Polymorphism, Genetic | 2 | 2005 | 1450 | 0.080 |
Why?
|
| Immunization | 1 | 2010 | 397 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2013 | 636 | 0.080 |
Why?
|
| Recurrence | 3 | 2017 | 4758 | 0.080 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 609 | 0.080 |
Why?
|
| Urban Population | 1 | 1989 | 269 | 0.080 |
Why?
|
| Research Design | 2 | 2013 | 1544 | 0.080 |
Why?
|
| Cytokines | 1 | 2017 | 2809 | 0.080 |
Why?
|
| Patient Compliance | 3 | 1999 | 667 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 1991 | 437 | 0.080 |
Why?
|
| Nutrition Assessment | 1 | 2008 | 169 | 0.080 |
Why?
|
| Internationality | 1 | 2008 | 208 | 0.080 |
Why?
|
| Tuberculoma, Intracranial | 1 | 2007 | 9 | 0.070 |
Why?
|
| Prognosis | 7 | 2016 | 21713 | 0.070 |
Why?
|
| Breast Feeding | 1 | 2008 | 239 | 0.070 |
Why?
|
| Bacteriological Techniques | 3 | 2012 | 121 | 0.070 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 308 | 0.070 |
Why?
|
| Pregnancy | 4 | 2008 | 7573 | 0.070 |
Why?
|
| Influenza, Human | 2 | 2010 | 925 | 0.070 |
Why?
|
| Brain Diseases | 2 | 1995 | 403 | 0.070 |
Why?
|
| Hospitalization | 2 | 1993 | 2083 | 0.070 |
Why?
|
| South Africa | 1 | 2006 | 92 | 0.070 |
Why?
|
| Amphotericin B | 1 | 1987 | 289 | 0.070 |
Why?
|
| Radiography | 3 | 2015 | 1904 | 0.070 |
Why?
|
| Dysentery, Bacillary | 1 | 1985 | 11 | 0.070 |
Why?
|
| Biomarkers | 1 | 2017 | 5047 | 0.070 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 317 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2015 | 9244 | 0.060 |
Why?
|
| Ethambutol | 1 | 2004 | 10 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 690 | 0.060 |
Why?
|
| Caregivers | 1 | 2011 | 677 | 0.060 |
Why?
|
| Colonic Diseases | 1 | 1985 | 71 | 0.060 |
Why?
|
| Prospective Studies | 7 | 2021 | 12873 | 0.060 |
Why?
|
| Molecular Epidemiology | 3 | 2013 | 246 | 0.060 |
Why?
|
| Infant, Premature, Diseases | 1 | 1987 | 245 | 0.060 |
Why?
|
| Candidiasis | 1 | 1987 | 262 | 0.060 |
Why?
|
| Intestinal Perforation | 1 | 1985 | 102 | 0.060 |
Why?
|
| Thoracic Diseases | 1 | 2004 | 31 | 0.060 |
Why?
|
| Animals | 5 | 2018 | 59536 | 0.060 |
Why?
|
| Bacteremia | 1 | 2010 | 689 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2010 | 672 | 0.060 |
Why?
|
| Tuberculosis, Cutaneous | 1 | 2003 | 5 | 0.060 |
Why?
|
| Cation Transport Proteins | 1 | 2005 | 199 | 0.060 |
Why?
|
| Treatment Failure | 3 | 2016 | 1391 | 0.060 |
Why?
|
| Syndrome | 1 | 2007 | 1351 | 0.060 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 1148 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 1945 | 0.060 |
Why?
|
| Visitors to Patients | 1 | 2002 | 9 | 0.060 |
Why?
|
| Linezolid | 1 | 2022 | 64 | 0.060 |
Why?
|
| Nutrition Disorders | 1 | 2002 | 57 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2023 | 210 | 0.050 |
Why?
|
| 3' Untranslated Regions | 1 | 2003 | 343 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2003 | 253 | 0.050 |
Why?
|
| Standard of Care | 1 | 2023 | 243 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2013 | 9180 | 0.050 |
Why?
|
| Prednisone | 2 | 2016 | 984 | 0.050 |
Why?
|
| Pneumonia | 1 | 1987 | 751 | 0.050 |
Why?
|
| Uganda | 1 | 2021 | 74 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 4367 | 0.050 |
Why?
|
| Body Fluids | 2 | 1996 | 125 | 0.050 |
Why?
|
| Travel | 2 | 2015 | 190 | 0.050 |
Why?
|
| DNA, Bacterial | 2 | 1995 | 558 | 0.050 |
Why?
|
| Drug and Narcotic Control | 1 | 2020 | 31 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2023 | 467 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2005 | 5539 | 0.050 |
Why?
|
| Mass Chest X-Ray | 1 | 2020 | 4 | 0.050 |
Why?
|
| Sputum | 1 | 2021 | 141 | 0.050 |
Why?
|
| Measles | 2 | 1991 | 36 | 0.050 |
Why?
|
| Disease Progression | 2 | 2010 | 6682 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 3890 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 78 | 0.050 |
Why?
|
| Genotype | 3 | 2016 | 4109 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2001 | 182 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 4938 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2018 | 6100 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 305 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1993 | 1489 | 0.040 |
Why?
|
| Lung | 1 | 2009 | 3151 | 0.040 |
Why?
|
| Algorithms | 3 | 2010 | 3890 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2018 | 73 | 0.040 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2018 | 87 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2008 | 2967 | 0.040 |
Why?
|
| Philippines | 1 | 1997 | 39 | 0.040 |
Why?
|
| Immunocompetence | 1 | 1997 | 75 | 0.040 |
Why?
|
| Proteus mirabilis | 1 | 2016 | 12 | 0.040 |
Why?
|
| Peru | 1 | 2016 | 52 | 0.040 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 34 | 0.040 |
Why?
|
| North America | 1 | 2016 | 314 | 0.030 |
Why?
|
| Meningitis | 1 | 2016 | 112 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 1997 | 205 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2016 | 193 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2005 | 239 | 0.030 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2015 | 23 | 0.030 |
Why?
|
| X-Rays | 1 | 1995 | 146 | 0.030 |
Why?
|
| Serologic Tests | 1 | 1995 | 137 | 0.030 |
Why?
|
| India | 1 | 2015 | 301 | 0.030 |
Why?
|
| Mastoiditis | 1 | 1995 | 26 | 0.030 |
Why?
|
| Hydrocephalus | 2 | 2013 | 217 | 0.030 |
Why?
|
| Pyrazinamide | 1 | 1994 | 11 | 0.030 |
Why?
|
| Lymph Node Excision | 2 | 2000 | 1959 | 0.030 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 1995 | 79 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 1996 | 222 | 0.030 |
Why?
|
| Tympanic Membrane | 1 | 1994 | 18 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 1183 | 0.030 |
Why?
|
| Eosinophilia | 1 | 2016 | 176 | 0.030 |
Why?
|
| Middle Ear Ventilation | 1 | 1994 | 20 | 0.030 |
Why?
|
| Automobile Driving | 1 | 1994 | 29 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 833 | 0.030 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2014 | 79 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2015 | 179 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 457 | 0.030 |
Why?
|
| Leg | 1 | 1995 | 226 | 0.030 |
Why?
|
| Infliximab | 1 | 2014 | 130 | 0.030 |
Why?
|
| Otitis Media | 1 | 1994 | 65 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 597 | 0.030 |
Why?
|
| Pregnancy in Adolescence | 1 | 1994 | 58 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 233 | 0.030 |
Why?
|
| Violence | 1 | 1994 | 116 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2020 | 1863 | 0.030 |
Why?
|
| Feces | 1 | 2017 | 770 | 0.030 |
Why?
|
| Risk-Taking | 1 | 1994 | 133 | 0.030 |
Why?
|
| Linkage Disequilibrium | 2 | 2005 | 460 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 980 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 1997 | 643 | 0.030 |
Why?
|
| Paraplegia | 1 | 2013 | 95 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 298 | 0.030 |
Why?
|
| Gastrostomy | 1 | 2014 | 180 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2013 | 55 | 0.030 |
Why?
|
| Head | 1 | 1994 | 249 | 0.030 |
Why?
|
| Abscess | 1 | 1994 | 177 | 0.030 |
Why?
|
| Survival Rate | 2 | 2015 | 12221 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 1997 | 1225 | 0.030 |
Why?
|
| Intestines | 1 | 2017 | 686 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1993 | 347 | 0.030 |
Why?
|
| Hyponatremia | 1 | 2013 | 82 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 1995 | 474 | 0.030 |
Why?
|
| Skin Diseases, Infectious | 1 | 1992 | 22 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2014 | 191 | 0.030 |
Why?
|
| Diphtheria | 1 | 1991 | 15 | 0.030 |
Why?
|
| Internet | 1 | 2016 | 706 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2012 | 226 | 0.020 |
Why?
|
| Haemophilus Infections | 1 | 1991 | 103 | 0.020 |
Why?
|
| Haemophilus influenzae | 1 | 1991 | 144 | 0.020 |
Why?
|
| Whooping Cough | 1 | 1991 | 62 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 1993 | 354 | 0.020 |
Why?
|
| DNA Probes | 1 | 1991 | 217 | 0.020 |
Why?
|
| Length of Stay | 1 | 2018 | 1900 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1993 | 414 | 0.020 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2010 | 16 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2010 | 82 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 2014 | 339 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2013 | 292 | 0.020 |
Why?
|
| Critical Illness | 1 | 2015 | 714 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 1053 | 0.020 |
Why?
|
| Leukocidins | 1 | 2010 | 46 | 0.020 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2010 | 128 | 0.020 |
Why?
|
| Health Promotion | 1 | 1994 | 502 | 0.020 |
Why?
|
| Societies, Medical | 1 | 1996 | 1335 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 1972 | 0.020 |
Why?
|
| Exotoxins | 1 | 2010 | 77 | 0.020 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2010 | 53 | 0.020 |
Why?
|
| Pneumococcal Infections | 1 | 1991 | 241 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1993 | 1021 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 1994 | 524 | 0.020 |
Why?
|
| Cambodia | 1 | 1988 | 12 | 0.020 |
Why?
|
| Encephalitis | 1 | 1990 | 143 | 0.020 |
Why?
|
| HIV-1 | 1 | 1993 | 653 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 2218 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2010 | 228 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 3441 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2014 | 732 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 2352 | 0.020 |
Why?
|
| Biopsy | 1 | 1995 | 3443 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 1989 | 288 | 0.020 |
Why?
|
| Infectious Mononucleosis | 1 | 1987 | 33 | 0.020 |
Why?
|
| Research | 1 | 1989 | 415 | 0.020 |
Why?
|
| Chronic Disease | 2 | 1994 | 1819 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 1994 | 860 | 0.020 |
Why?
|
| Hyperbilirubinemia | 1 | 1987 | 78 | 0.020 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1987 | 58 | 0.020 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1987 | 46 | 0.020 |
Why?
|
| Craniotomy | 1 | 1988 | 304 | 0.020 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1987 | 69 | 0.020 |
Why?
|
| Species Specificity | 1 | 1987 | 777 | 0.020 |
Why?
|
| Keratitis | 1 | 1987 | 102 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1992 | 717 | 0.020 |
Why?
|
| Shigella flexneri | 1 | 1985 | 15 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2005 | 139 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1987 | 875 | 0.020 |
Why?
|
| Absorption | 1 | 2004 | 81 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1989 | 554 | 0.020 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2004 | 27 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2005 | 242 | 0.020 |
Why?
|
| Kinetics | 1 | 1987 | 2049 | 0.010 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2003 | 29 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2010 | 1029 | 0.010 |
Why?
|
| Pericardial Effusion | 1 | 2004 | 118 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 1399 | 0.010 |
Why?
|
| Patient Isolation | 1 | 2002 | 25 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2004 | 700 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2004 | 201 | 0.010 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2002 | 58 | 0.010 |
Why?
|
| Family | 1 | 2005 | 736 | 0.010 |
Why?
|
| Cranial Nerves | 1 | 1995 | 20 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1987 | 7222 | 0.010 |
Why?
|
| Mastoid | 1 | 1994 | 26 | 0.010 |
Why?
|
| Granulation Tissue | 1 | 1994 | 26 | 0.010 |
Why?
|
| Aminoglycosides | 1 | 1994 | 220 | 0.010 |
Why?
|
| Middle Aged | 3 | 2010 | 86204 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 6009 | 0.010 |
Why?
|
| Drainage | 1 | 1994 | 416 | 0.010 |
Why?
|
| Aged | 2 | 2004 | 70117 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2003 | 4549 | 0.010 |
Why?
|
| Wound Healing | 1 | 1995 | 815 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 4917 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 6089 | 0.010 |
Why?
|
| Shigella sonnei | 1 | 1987 | 3 | 0.000 |
Why?
|
| Mice | 1 | 1987 | 34495 | 0.000 |
Why?
|
| Cornea | 1 | 1987 | 638 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1995 | 5542 | 0.000 |
Why?
|